Analyst Price Target is $30.00
▲ +930.93% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Mind Medicine (MindMed) in the last 3 months. The average price target is $30.00, with a high forecast of $75.00 and a low forecast of $5.00. The average price target represents a 930.93% upside from the last price of $2.91.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in Mind Medicine (MindMed).
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.